The technology outlined in this study can be used to predict the onset of stomach cancer in its early stages. This study introduces methodologies for producing information that can help predict the different stages of cancer. More specifically, this technology measures levels of ADAM8 expression or genes coding for ADAM8 in liquid biopsy samples to diagnose cancer in its early stages and to predict the N-stages of cancer. This technology is non-invasive and is simpler, faster, and more than existing methodologies that use tissue extracted through endoscopies or surgical procedures to measure the expression levels of biomarkers for disease.
Recently, in the Republic of Korea and Japan, the survival rates for patients with stomach cancer have increased significantly due to improved early detection. However, around the world, survival rates for stomach cancer are still rather low, especially for patients who are in Stage 3 or later, due to the cancer’s high resistance to anti-cancer medications. In ROK and Japan, one of the reasons for the increase in survival rates for patients with stomach cancer is early detection through the inclusion of endoscopies for all individuals undergoing physical examinations. Although these procedures are conducted widely throughout the general population, endoscopies for stomach cancer are not only expensive, but also are invasive and put patients at risk for hemorrhaging, esophageal damage, and complications through the use of anesthesia, thus making them difficult to conduct frequently. By using unique biomarkers for stomach cancer found in the blood, early diagnosis and treatment, as well as any additional testing to predict the onset and prognosis of cancer, can be conducted at a much lower cost with lower risk and higher efficiency. However, the development of technologies that can identify biomarkers for the detection of stomach cancer is still in the early stages. The technology presented in this study includes a blood diagnostic kit that uses the ADAM8 protein and the genome responsible for coding this protein. The use of this kit is cost efficient, low-risk, and highly effective at the early detection of stomach cancer and determining the prognosis for the disease. This technology includes materials, a kit, and information to allow for the early detection of the onset of stomach cancer and to predict its stages of development.